CJC-1295 vs Ipamorelin — Mechanism, Evidence & Regulatory Comparison
CJC-1295 and ipamorelin stimulate growth-hormone release through entirely different receptor systems — CJC-1295 acts as a GHRH analog targeting GHRH receptors on the pituitary, while ipamorelin is a ghrelin-receptor agonist (GHRP) acting on GHS-R1a. Both are sold in the research market for laboratory study, but neither is FDA-approved, and their safety profiles, half-lives, and evidence maturity differ significantly.
Mechanism Comparison
| Property | CJC-1295 (GHRH Analog) | Ipamorelin (GHS-R1a Agonist) |
|---|---|---|
| Receptor target | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Mechanism class | Growth hormone-releasing hormone analog | Growth hormone-releasing peptide |
| Half-life | ~30 min (no-DAC) to 6–8 days (with DAC) | ~2 hours |
| FDA approval | None identified | None identified |
| Research focus | GHRH-receptor stimulation studies | Ghrelin-pathway selectivity research |
| Key distinction | Direct GHRH-receptor stimulation mimics endogenous GHRH | Ghrelin-mimetic; GH release via a separate pathway |
Evidence Maturity
| Dimension | CJC-1295 (GHRH Analog) | Ipamorelin (GHS-R1a Agonist) |
|---|---|---|
| Clinical trials | None registered for CJC-1295 specifically | None registered for ipamorelin specifically |
| Preclinical depth | Limited GHRH analog characterization available | Established GHS-R1a agonist profile in literature |
| Buyer evidence | Claims often exceed what is publicly documented | Commonly discussed; mechanistic data limited |
Regulatory Status
Neither CJC-1295 nor ipamorelin holds FDA approval for any indication. Both are sold in the research market as chemicals for laboratory study only. Neither product should be confused with any FDA-approved pharmaceutical. The FDA has issued guidance on unapproved peptide products and compounding risks.
Quality and COA Checklist
- Third-party COA: Both compounds should have batch-linked certificates from independent laboratories
- Purity ≥98%: HPLC/MS data should be visible — not just a stated percentage
- Research-use-only labeling: Vendors should not provide dosing, injection, or human-use guidance
- Transparent payment: Legitimate vendors have clear business payment methods and refund policies
- Source dating: COAs should be within the last 6–12 months for current inventory
Frequently Asked Questions
Are CJC-1295 and ipamorelin the same thing?
No. They act on completely different receptors — CJC-1295 targets GHRH receptors while ipamorelin targets ghrelin receptors (GHS-R1a). They are sometimes discussed together because both can stimulate GH release, but they do so through separate mechanisms.
Is CJC-1295 or ipamorelin FDA-approved?
Neither compound has received FDA approval for any indication. Both are available in the research market as chemicals for laboratory study only.
Which has a longer half-life?
CJC-1295 with DAC has by far the longest half-life (6–8 days). CJC-1295 without DAC (MOD GRF 1-29) has a ~30-minute half-life. Ipamorelin's half-life is approximately 2 hours. Half-life differences are relevant for understanding how each compound behaves in research settings.
Why are they often discussed together?
Both stimulate GH release and are popular in research-vendor catalogues. They are sometimes studied in combination models, though the mechanisms are independent — GHRH receptor (CJC-1295) versus ghrelin receptor (ipamorelin). This page does not address stacking or combination use.
Where can I buy CJC-1295 or ipamorelin?
Both are available from research peptide vendors for laboratory study. This publication reviews vendors on documentation quality and transparency, not on product availability. Check vendor COAs before purchasing.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for CJC-1295 vs Ipamorelin — Mechanism, Evidence & Regulatory Comparison
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For cjc 1295 vs ipamorelin, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →